Subscribe to our channel http://bit.ly/AJSubscribe

Subscribe to our channel http://bit.ly/AJSubscribe

Swiss drugmaker Novartis has lost a battle in India's highest court to patent an updated version of its cancer drug Gilvec. The Supreme Court rejected the application because the new version differs only slightly from the old one. The landmark ruling sets a precedent for patents on all existing medicines in India. Updating drugs to obtain new patents is known as evergreening. Novartis has stated that the change took years of research and makes the drug more effective, and the company has successfully patented the new version in nearly 40 other countries.

At Al Jazeera English we focus on people and events that impact people's lives. We bring to light topics that often remain underexposed, listen to all sides of the story and give a 'voice to the voiceless'.
Our viewers reach more than 270 million households in more than 140 countries around the world and trust Al Jazeera English to keep them informed, inspired and entertained.
Our unbiased, fact-based reporting wins praise and respect worldwide. It's our unique brand of journalism that the world has come to rely on.
We are reshaping the global media and continuously working to strengthen our reputation as one of the world's most respected news and current affairs channels.

Social Media Links:

Facebook: https://www.facebook.com/aljazeera
Instagram: https://instagram.com/aljazeera/?ref…
Twitter: https://twitter.com/ajenglish
Website: http://www.aljazeera.com/
Google: https://plus.google.com/aljazeera/posts

Please take the opportunity to connect and share this video with your friends and family if you find it helpful.